AstraZeneca Restores Supply Of Key Recalled Products In India; Plans To Outsource Manufacturing And Launch More Drugs
This article was originally published in PharmAsia News
After being battered by a government probe and voluntary recalls earlier this year, the company appears to be gearing up for a stronger presence in India.
You may also be interested in...
MUMBAI - As Pfizer Inc. looks to potentially spin-off its emerging markets unit and analysts talk openly about spin-outs for other companies as well, industry watchers may want to take a closer look at India, where several Big Pharma have had separately listed subsidiaries for decades
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.